Abstract Artificial lung devices comprised of hollow fiber membranes (HFMs) coated with the enzyme carbonic anhydrase (CA), accelerate removal of carbon dioxide (CO 2 ) from blood for the treatment of acute respiratory failure. While previous work demonstrated CA coatings increase HFM CO 2 removal by 115 % in phosphate buffered saline (PBS), testing in blood revealed a 36 % increase compared to unmodified HFMs. In this work, we sought to characterize the CO 2 mass transport processes within these biocatalytic devices which impede CA coating efficacy and develop approaches towards improving bioactive HFM efficiency. Aminated HFMs were sequentially reacted with glutaraldehyde (GA), chitosan, GA and afterwards incubated with a CA solution, covalently linking CA to the surface. Bioactive CA-HFMs were potted in model gas exchange devices (0.0119 m 2 ) and tested for esterase activity and CO 2 removal under various flow rates with PBS, whole blood, and solutions containing individual blood components (plasma albumin, red blood cells or free carbonic anhydrase). Results demonstrated that increasing the immobilized enzyme activity did not significantly impact CO 2 removal rate, as the diffusional resistance from the liquid boundary layer is the primary impediment to CO 2 transport by both unmodified and bioactive HFMs under clinically relevant conditions. Furthermore, endogenous CA within red blood cells competes with HFM immobilized CA to increase CO 2 removal. Based on our findings, we propose a bicarbonate/CO 2 disequilibrium hypothesis to describe performance of CA-modified devices in both buffer and blood. Improvement in CO 2 removal rates using CA-modified devices in blood may be realized by maximizing bicarbonate/ CO 2 disequilibrium at the fiber surface via strategies such as blood acidification and active mixing within the device.
Introduction
Removal of CO 2 from circulating blood using extracorporeal gas exchange devices is a promising treatment for acute respiratory failure [1] [2] [3] [4] [5] [6] [7] . Current respiratory assist devices used for extracorporeal carbon dioxide removal (ECCO 2 R) can require blood flow rates in excess of 1 L/ min to extract a clinically therapeutic 50 % of metabolic CO 2 production (*100 mL/min), necessitating larger cannula inserted by surgeons, rather than the intensivists typically treating these patients. This has been one reason ECCO 2 R has seen limited widespread use in ICUs [1, 7] . New technologies that facilitate accelerated CO 2 removal may lead to the development of smaller, more efficient respiratory assist devices that can be implemented by intensivists and other nonsurgical clinicians. We recently developed strategies to covalently immobilize the enzyme carbonic anhydrase (CA) to the surface of hollow fiber membranes (HFMs), as a means to increase CO 2 removal efficiency in respiratory assist devices. CA plays a critical role in blood carbon dioxide transport by catalyzing the reaction CO 2 2 , increasing the CO 2 partial pressure (PCO 2 ) at the fiber surface and increasing CO 2 flux through the membrane. Previous studies demonstrated bioactive CA-HFMs increase CO 2 removal by 115 % in phosphate buffered saline (PBS) and 37 % in blood, compared to unmodified fibers [8, 9] .
The difference in CA-HFM catalyzed CO 2 removal between PBS and blood is not well understood. Compared to our current 30-40 % increase in blood CO 2 removal, we anticipate at least 100 % increase will be necessary for the development of next-generation minimally invasive devices. Since both fluid systems operate under the same PCO 2 of 50 mmHg, other predominant blood factors, such as RBCs or plasma proteins, must limit the CA coating performance in whole blood. The presence of endogenous CA within RBCs may compete with immobilized CA, reducing the coating efficacy [10] . Additionally, adsorption of plasma proteins and platelets are well known contributors to thrombus formation on the surfaces of polymeric materials, decreasing transport across the fibers and performance of respiratory assist devices [11] . Our use of immobilized CA on the surface of blood contacting gas exchange membranes is a new development in the field. Examining the kinetics of CO 2 transport within CA-modified gas exchange devices in both PBS and blood is an important step towards elucidating strategies for improved CO 2 removal efficiency.
In this study we examined the mass transport phenomena governing CO 2 removal using bioactive CA-HFMs in gas exchange modules. The roles of immobilized CA activity, liquid flow rate and blood cells and proteins were clarified. Using either high activity human or low activity bovine enzyme sources, CA II was immobilized onto HFMs. The CA modified HFMs were fabricated into model gas exchange devices to assess CO 2 removal performance from fluids containing individual blood components, PBS, PBS ? 5 % Albumin, PBS ? CA, PBS ? RBC and whole blood under a mass transfer environment similar to those of commercially available oxygenators. The results of this study will be used to develop respiratory assist devices in which bioactive CA-HFMs can be employed and more substantially increase CO 2 exchange in blood.
Methods

Materials
Carbonic anhydrase II from bovine erythrocytes, glutaraldehyde (GA), chitosan (MW = 50-190 kD, based on viscosity) and glacial acetic acid were purchased from Sigma-Aldrich (St. Louis, MO). Purified recombinant human carbonic anhydrase II was provided by Dr. Silverman and Dr. McKenna from University of Florida (Gainesville, FL) [12] . Commercial microporous polypropylene HFMs (Celgard TM ; OD 300 lm, ID 240 lm, Membrana GmbH, Wuppertal, Germany) were obtained from ALung Technologies, Inc. (Pittsburgh, PA) with an aminated-siloxane coating. Bovine blood with Na-heparin anticoagulation (1:100 dilution of 1000 U/mL) was purchased from Lampire Biological Laboratories (Pipersville, PA). All other reagents were purchased from Sigma-Aldrich and were of analytical grade or purer.
2.2
In vitro CO 2 exchange in scaled down modules of CA-HFM CA immobilization onto HFMs was performed as previously detailed [9] . A scaled-down gas exchange module was fabricated and an in vitro recirculating test loop was used to assess CO 2 gas exchange rates using unmodified HFMs and CA-immobilized HFMs ( Fig. 1) . For each device the fluid inlet/outlet PCO 2 and resulting F CO 2 were measured in triplicate. The _ VCO 2 for each model gas exchange device is reported as an average of these measurements. The difference in PCO 2 from the device inlet to the outlet (PCO 2 inlet-PCO 2 outlet) is reported as PCO 2 drop.
The testing fluids were created as described. PBS: A PBS solution was prepared with a final pH 7.4 and PCO 2 of 50 mmHg by diluting 780 mL PBS to 1 L with deionized water and adding 30 mMol sodium hydroxide. The basic PBS solution was introduced to the gas exchange loop and upon solvation of CO 2 gas, carbonic acid is formed, decreasing PBS pH to physiologic 7.4. PBS ? 5 % albumin: PBS was prepared as described, and once PCO 2 equilibrated to 50 mmHg, lyophilized bovine serum albumin was dissolved to 5 % (w/v). PBS ? carbonic anhydrase: PBS was prepared as described, and once PCO 2 equilibrated to 50 mmHg lyophilized bovine carbonic anhydrase II was added to 16 lM. This concentration was selected to mimic physiologic RBC CAII concentration [13] . PBS ? RBC: RBCs were isolated from heparinized whole bovine blood and suspended in PBS. Whole bovine blood was centrifuged at 2500 RCFs for 10 min and the buffy coat discarded. Packed RBCs were rinsed in PBS under gentle shaking for 10 min, centrifuged again and repeated, for a total of three wash steps. Packed RBCs were suspended in PBS to 35 % hematocrit, glucose was adjusted to 100-300 mg/dL prior to use by the addition of 5 % dextrose solution and allowed to incubate for 1 h [14] . Bovine Blood: Heparinized bovine blood was purchased from Lampire Biological Labs (Pipersville, PA), glucose was adjusted to 100-300 mg/dL by the addition of 5 % dextrose solution and hematocrit to 35 %, and allowed to incubate for 1 h [14] .
Carbonic anhydrase esterase activity assay
Immobilized CA enzyme activity was measured spectrophotometrically by monitoring the hydrolysis of p-nitrophenyl acetate (p-NPA) to p-nitrophenol (p-NP) at 412 nm. CA-modified fibers were fabricated into model oxygenators as described in Sect. 2.2 and a recirculating loop of 15 mL, 100 mM phosphate buffer pH 7.5, 80 lM p-NPA was setup to measure the esterase activity under 45, 90 and 200 mL/min flow rate. Absorbance measurements at 412 nm were recorded every minute over a 5 min period, and plotted as a function of time. One activity unit was defined as the amount of enzyme required to generate 1 lmol pNP per minute.
Statistical analyses
All data are presented as a mean with standard deviation. Statistical significance between sample groups was determined using ANOVA followed by post hoc Tukey testing of specific differences. All other data was compared using a Student's t test assuming equal sample variance. Differences were considered statistically significant for P \ 0.05.
Results
Immobilized CA-HFM activity: bovine versus human
Human and bovine CAII HFMs were characterized for both immobilized esterase activity (lmol/min) and CO 2 removal rate (mL/min/m 2 ) in PBS buffer. Human CA-HFMs demonstrated a fivefold increase in immobilized esterase activity compared to bovine CA-HFMs, 8.7 and 1.7 U respectively (Fig. 2) . Flow induced shear under clinically relevant mass transport conditions did not affect immobilized CA esterase activity, as increasing fluid flow rate between 45 and 200 mL/min had negligible effects on immobilized CA activity. In contrast to the esterase activity assay, bovine and human CA devices demonstrated similar CO 2 removal rates. At 45 mL/min PBS flow rate, unmodified HFMs removed 85 mL/min/m 2 while bovine and human CA-HFMs removed 135 and 143 mL/min/m 2 respectively (Fig. 3) . Human CA devices attained marginally Fig. 1 Diagram of a model respiratory device and experimental setup for measuring CO 2 removal rates of unmodified and modified HFMs. Bovine blood or PBS solutions were perfused over the outside of the fibers while oxygen sweep gas was passed through the fiber lumens in the opposite direction. Deoxygenator employed the use of a heat exchanger to maintain blood temperature at 37°C higher (\10 %) removal rates over bovine CA devices with increasing PBS flow rate. This result indicates that the current level of immobilized bovine CA activity is not a limiting factor in the CO 2 removal rate of bioactive CAHFMs. Increasing p-NPA activity from 1.8 (bovine) to 8.8 U (human) did not dramatically increase gas exchange. 2 removal rates CO 2 removal rates were assessed on unmodified and human CA-HFMs in PBS, PBS ? 5 % Albumin, PBS ? CA, PBS ? RBC, and whole blood under a mass transfer environment similar to those of commercially available oxygenators. Albumin solution had no negative effects on CO 2 removal performance by unmodified or CA-HFMs. In PBS and PBS ? 5 % albumin, unmodified HFMs removed 75 and 88 mL/min/m 2 respectively, while CA-HFMs removed 154 and 187 mL/min/m 2 respectively, for a 106 % (PBS) or 112 % (PBS ? 5 % albumin) increase in CO 2 removal rate (Fig. 4) Bioactive CA-HFM CO 2 removal rate and fluid PCO 2 were assessed in whole bovine blood with varying flow rates. Increasing fluid flow rate adversely affects CA-HFM performance, with a 37, 22 and 13 % increase in CO 2 removal at 45, 90 and 200 mL/min, respectively (Fig. 5) . The difference in PCO 2 from device inlet to outlet (PCO 2 drop) decreased from 13.9 mmHg at 45 mL/min to 11.0 mmHg at 90 mL/min and 5.0 mmHg at 200 mL/min (Fig. 6 ) (P \ 0.01). This PCO 2 drop behavior was similar between unmodified and CA-HFMs within each flow rate. Increasing fluid flow decreased CO 2 removal per unit volume passing through the scaled-down gas exchange module, and adversely affected CA coating contribution to total CO 2 removal rate. Increasing PCO 2 drop improves bioactive CA-HFMs performance.
Blood component effects on CA-HFM CO
Discussion
The goal of this study was to examine the kinetics of CO 2 transport within CA-modified gas exchange devices in PBS and blood, as a means to elucidate strategies for improved blood CO 2 removal using CA-HFM devices. We employed two forms of CA to empirically evaluate the kinetics and mass transport processes limiting HFM CO 2 removal in prototype gas exchange devices. The CO 2 removal performance by CA-HFMs is not influenced by immobilized CA activity or adsorption of blood plasma proteins (albumin). In blood, endogenous CA within RBCs participate along with surface immobilized CA to catalyze bicarbonate/CO 2 equilibrium, in effect throttling immobilized CA. The mass transport processes for CO 2 removal by CAmodified gas exchange devices is comprised of four distinct physicochemical processes. Overall mass transport in the system is governed by the individual resistances of each process in series. The first resistance in HFM CO 2 removal is interconversion between bicarbonate and CO 2 within the bulk fluid, catalyzed by endogenous CA in blood or uncatalyzed in PBS. Second is diffusion of bicarbonate and CO 2 from the bulk fluid into the liquid diffusional boundary layer adjacent to the HFM surface. Third is the catalyzed dehydration of bicarbonate to CO 2 by immobilized CA on the HFM surface. Last is the diffusion of gaseous CO 2 through the membrane and into the HFM sweep gas stream. Previous work demonstrated the rate limiting step in CO 2 removal for unmodified HFMs is diffusion of CO 2 through the liquid-side diffusional boundary layer, not diffusion through the HFM itself [15, 16] . In this application we must additionally consider the impact of immobilized CA catalytic rates, and equilibrium between bicarbonate/CO 2 on system-wide CO 2 transport. The importance of immobilized CA activity on CO 2 removal was studied through human and bovine CA. Immobilized human CA has fivefold increase in p-NPA activity over bovine CA, likely due to greater purity of the recombinant human CA solution as compared to the lyophilized bovine CA containing contaminants and denatured proteins. In previous studies, increasing immobilized CA activity through more efficient conjugation strategies increased CO 2 removal rates [9] . We hypothesized higher activity human CA-HFMs would increase CO 2 removal over bovine CA-HFMs. In contrast to the p-NPA assay, CO 2 removal rates were comparable between human and bovine CA-HFMs (Fig. 3) . Gas exchange was performed in PBS to avoid effects from protein adsorption on the fiber surface or endogenous CA. Chitosan immobilized CA resulted in sufficient activity such that increasing immobilized CA activity with human CA no longer increased CO 2 removal rate. This suggests diffusive resistance within the liquid boundary layer, as with unmodified HFMs, is the rate limiting step for CO 2 transport rather than immobilized enzyme activity. CA catalyzes bicarbonate/CO 2 and p-NPA/p-NP using the same active site, however the rate constant (k) is 1 million times greater for CO 2 , 1 9 10 6 s -1 for CO 2 versus 1 s -1 for p-NPA [17, 18] . CA catalyzed conversion of bicarbonate/CO 2 is fast enough such that diffusion through the boundary layer dominates transport resistance [19, 20] . Decreasing boundary layer resistance by increasing fluid flow rate, increases delivery of p-NPA to the fiber surface, but does not increase p-NPA catalysis by immobilized CA (Fig. 2) . Differences in immobilized CA activity are measurable with the p-NPA assay because CA p-NPA catalysis is the rate limiting resistance compared to the fluid boundary layer diffusional resistance. Conversely for bicarbonate or CO 2 as the enzyme substrate, the boundary layer resistance dominates as the rate limiting step over the CA CO 2 catalytic rate. Divergence in the human and bovine CA curves with increasing flow rate in Fig. 3 is interpreted as reduction in boundary layer thickness (resistance) with increasing flow rate. This hypothesis is supported by regression fits to the data resulting in exponents approaching 0.5, which is the theoretical relationship between boundary layer thickness and liquid flow rate [15] . Due to the extremely fast catalytic rate of CA (among the highest known) [17] , strategies to improve CO 2 removal efficacy through increased CA loading or activity on the fiber surface are not productive avenues unless a corresponding decrease in diffusional boundary layer resistance can be achieved.
The performance of CA-HFMs were examined in whole blood at 45, 90 and 200 mL/min and compared with unmodified HFMs. Increasing blood flow rate increased CO 2 removal rate for unmodified and CA-HFMs, by decreasing the fluid boundary layer resistance. A decrease in CA coating enhancement from 37 to 13 % was observed with increasing blood flow rate from 45 to 200 mL/min (Fig. 5) . Shear-induced enzyme activity loss as a consequence of increased liquid flow rate is a potential hypothesis. Data from p-NPA activity assay suggest fluid induced shear did not negatively impact CA under these flow rates (Fig. 2) . Additionally, CO 2 removal at 45 mL/min is repeatable after exposure to 200 mL/min flow rate (data not shown), indicating permanent shear-induced effects are unlikely, although transient shear effects under clinically relevant conditions still need to be explored. While increasing blood flow rate increases total CO 2 removal, fluid residence time within the device decreases and consequently the CO 2 removal per fluid volume declines (Fig. 6 ). In PBS, HFMs remove CO 2 faster than bicarbonate can dehydrate to CO 2 (uncatalyzed), resulting in a pool of bicarbonate as PBS is depleted of gaseous CO 2 . As a drop in bulk PCO 2 is observed, disequilibrium between bicarbonate/CO 2 is created. Approximately 10 3 CO 2 molecules are removed per second by CA-HFMs at a liquid flow rate of 45 mL/min, while the uncatalyzed bicarbonate to CO 2 conversion rate is *1 s -1 . Bioactive CA-HFMs facilitate the dehydration reaction to restore CO 2 pressure in the fluid boundary layer. In blood, endogenous CA within RBCs catalyzes bicarbonate/CO 2 conversion in the bulk fluid, but cannot maintain equilibrium within the fluid boundary layer, evidenced by the impact of CA coatings on HFM CO 2 removal. The fluid PCO 2 drop can be considered a metric of disequilibrium between bicarbonate and CO 2 where the higher the fluid flow rate, the smaller the PCO 2 drop, and the smaller the impact of bioactive CA coatings on HFM CO 2 removal.
We consistently observed a significant reduction in CA coating efficacy in blood compared to PBS. CO 2 removal by bioactive CA-HFMs was assessed in solutions containing individual blood components: plasma protein albumin, free CA and RBCs. Protein adsorption onto CAHFMs did not decrease CO 2 removal by unmodified or CAHFMs. In contrast, endogenous CA within circulating RBCs reduced enhancement of the immobilized CA coating on CO 2 removal. Blood maintains bicarbonate/CO 2 equilibrium more effectively than PBS and directly limits the CA-HFM CO 2 removal enhancement, evident by the 106 % increase in CO 2 removal (PBS) versus 37 % increase (blood). RBC CA solutions increased CO 2 removal rates for both unmodified and CA-immobilized devices compared to PBS solution (Fig. 4) . Free CA spiked in PBS decreased CA coating efficacy to only 7 % improvement over non CA-HFM devices. Since CA-HFM performance increases when CA is localized to RBCs (7 % free CA vs. 27 % RBC CA), diffusion of bicarbonate/CO 2 across the RBC membrane potentially contributes to the resistance limiting bulk fluid equilibrium from restoring gaseous CO 2 as it is depleted by HFMs. Free CA spiked in PBS may localize closer to the HFM surface similar to immobilized CA, whereas RBCs tend to migrate away from stationary surfaces due to hydrodynamic forces, a phenomenon known as the Fahraeus effect for blood flow in small tubes [21] . Development of improved and more efficient respiratory assist devices will enable next generation, minimally invasive extracorporeal support of failing lungs at low blood flows. Carbonic anhydrase immobilized on HFMs is a novel approach to increase CO 2 removal rates, but the factors limiting the enhancement of CO 2 removal by CA-HFMs were not well understood. Our results demonstrate bioactive CA-HFMs operate under Le Chatelier's principle, catalyzing conversion of bicarbonate/CO 2 to preserve chemical equilibrium within the fluid boundary layer. In blood, endogenous CA within RBCs also catalyzes bicarbonate/CO 2 equilibrium, in effect throttling immobilized CA's contribution towards CO 2 removal. Mechanisms which reduce the diffusional boundary layer resistance and conditions which promote local bicarbonate/CO 2 disequilibrium, such as fluid longer transit times, will result in the largest contribution from the CA coating. Development is underway on CO 2 removal devices which reduce the boundary layer resistance by increasing fluid velocity past HFMs through mechanical mixing independent of fluid flow rate through the device [22] [23] [24] . This approach increases delivery of bicarbonate/ CO 2 to the HFM surface without decreasing blood transit time, which may take advantage of CA's rapid catalysis and boost CO 2 removal performance from increased substrate delivery. Active mixing and CA-HFMs can only restore equilibrium within the fluid boundary layer, but cannot augment fluid PCO 2 above the device inlet condition (around 50 mmHg). Since bicarbonate/CO 2 equilibrium is described by CO 2 þ H 2 O() CA HCO À 3 þ H þ , increasing the H ? concentration in the fluid boundary layer will create disequilibrium, forcing CA to catalyze dehydration of bicarbonate, increasing fluid PCO 2 beyond the inlet 50 mmHg, and driving further improvement in HFM CO 2 removal. By using an acidic gas within the oxygen sweep gas passed through the HFM lumens, an acid product can be introduced to the fluid boundary layer, creating local disequilibrium while minimizing acidification of the whole bulk fluid. In subsequent work we demonstrate dilute sulfur dioxide in oxygen sweep gas increases CO 2 removal, and when used in combination with bioactive CA-HFMs has a synergistic effect to more than double CO 2 removal while maintaining physiologic pH [25] .
